Innoviva EPS - Earnings per Share 2010-2024 | INVA

Innoviva eps - earnings per share from 2010 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Innoviva Annual EPS
2023 $2.20
2022 $2.37
2021 $2.87
2020 $2.02
2019 $1.43
2018 $3.53
2017 $1.17
2016 $0.53
2015 $-0.16
2014 $-1.50
2013 $-1.67
2012 $-0.20
2011 $-1.41
2010 $-1.16
2009 $-1.35
Innoviva Quarterly EPS
2024-03-31 $0.46
2023-12-31 $0.78
2023-09-30 $0.98
2023-06-30 $0.02
2023-03-31 $0.42
2022-12-31 $-0.64
2022-09-30 $2.80
2022-06-30 $0.01
2022-03-31 $0.20
2021-12-31 $0.23
2021-09-30 $0.90
2021-06-30 $0.90
2021-03-31 $0.84
2020-12-31 $0.48
2020-09-30 $0.26
2020-06-30 $0.69
2020-03-31 $0.59
2019-12-31 $0.42
2019-09-30 $0.36
2019-06-30 $0.34
2019-03-31 $0.31
2018-12-31 $2.34
2018-09-30 $0.43
2018-06-30 $0.49
2018-03-31 $0.27
2017-12-31 $0.51
2017-09-30 $0.21
2017-06-30 $0.30
2017-03-31 $0.15
2016-12-31 $0.23
2016-09-30 $0.13
2016-06-30 $0.13
2016-03-31 $0.04
2015-12-31 $0.04
2015-09-30 $-0.04
2015-06-30 $-0.07
2015-03-31 $-0.09
2014-12-31 $-0.12
2014-09-30 $-0.19
2014-06-30 $-0.57
2014-03-31 $-0.62
2013-12-31 $-0.47
2013-09-30 $-0.44
2013-06-30 $-0.37
2013-03-31 $-0.39
2012-12-31 $-0.33
2012-09-30 $-0.37
2012-06-30 $-0.42
2012-03-31 $0.93
2011-12-31 $-0.45
2011-09-30 $-0.37
2011-06-30 $-0.31
2011-03-31 $-0.28
2010-12-31 $-0.24
2010-09-30 $-0.29
2010-06-30 $-0.28
2010-03-31 $-0.35
2009-12-31 $-0.34
2009-09-30 $-0.35
2009-06-30 $-0.35
2009-03-31 $-0.31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.998B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62